🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchInsulin icodec (Awiqli) — need advice Page 6

Insulin icodec (Awiqli) — need advice

VendorMark Mon, Feb 2, 2026 at 1:53 AM 31 replies 1,494 viewsPage 6 of 7
RegAffairsDC
Member
678
3,456
May 2024
Washington, DC
Feb 8, 2026 at 5:25 AM#26
TrialTracker_MD said:
Keep the original post as written when you update it, and add the correction underneath.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.

6 4amy_econ_NJ, bbq_ray_KC, oliver_london and 3 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Feb 8, 2026 at 8:57 PM#27
TrialTracker_MD said:
Keep the original post as written when you update it, and add the correction underneath.

Agreed on the substance. I would put less weight on the timescale, because two months of anything is not enough to distinguish a trend from a wobble.

Last edited: Feb 9, 2026 at 1:57 AM
7 5pam_stl, wei_SG, cory_ATX and 4 others
Reply Quote Save Share Report
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Feb 9, 2026 at 12:28 PM#28
TrialTracker_MD said:
Keep the original post as written when you update it, and add the correction underneath.

This is exactly what I could not find anywhere else.

8 6TomTeleRx, DoseLogDan, SleepFixSam and 5 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Feb 10, 2026 at 3:59 AM#29

Clinical perspective, offered as context rather than as advice. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

Last edited: Feb 10, 2026 at 8:59 AM
9 7pete_nash, hank_denver, carlos_SATX and 6 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Feb 10, 2026 at 7:29 PM#30

Closing the loop on my own question.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

31 4claudia_zurich, nancy_portland, rick_sfbay and 28 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register